Oral delivery system for tetanus toxoid

Authors

  • VJ AHIRE Center of Relevance and Excellence in New Drug Delivery Systems (TIFAC-CORE in NDDS), Department of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India.
  • JB DOSHI Toxoid Purifi cation Department, Serum Institute of India Pvt Ltd., 212/2, Soli Poonawala Road, Hadapsar, Pune, India
  • SD RAVETKAR Toxoid Purifi cation Department, Serum Institute of India Pvt Ltd., 212/2, Soli Poonawala Road, Hadapsar, Pune, India
  • KK SAWANT Center of Relevance and Excellence in New Drug Delivery Systems (TIFAC-CORE in NDDS), Department of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India.

Keywords:

Chitosan, Mucosal immunity, Systemic immunity, Tetanus toxoid

Abstract

Systemic and local immune response against tetanus toxoid (TT) encapsulated in chitosan (CS) microparticles (CSTT)prepared by ionic cross-linking using Sodium Tripolyphosphate (STPP) was studied. CS-TT microparticles, TTin PBS and plain CS microparticles were orally administered to mice and TT (adsorbed) was administered throughintramuscular route. Sera were analyzed for anti-TT IgG and intestinal lavage for anti-TT IgA levels using an ELISA.The study shows the effi cacy of chitosan microparticle suspension system, containing a TT, in inducing the IgA inintestine and IgG in systemic circulation.

Downloads

Download data is not yet available.

References

O’Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 1998; 34: 305-320.

Van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. Chitosan microparticles for Mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 2003; 21: 1400-1408.

Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 1996; 14(17/18): 1677-1685.

Damge C, Aprahamian M, Humbert W, Pinget M. Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J Pharm Pharmacol 2000; 52: 1049-1056.

Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled release in the gut associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer’s patches. J Contr Rel 1990;11: 205-214.

Ahire VJ, Sawant KK. Development of Rocket Electrophoresis Technique as an Analytical Tool in Preformulation Study of Tetanus Vaccine Formulation. Drug Dev Ind Pharm 2006; 32(7): 799-808.

Radi H, Mansoor A. Chitosan based gastrointestinal delivery systems. J Contr Rel 2003; 89: 151-165.

Singla AK, Chawla Chitosan M: Some pharmaceutical and biological aspects- An update. J Pharm Pharmacol 2001; 53:1047-1067.

Coppi G, Iannuccelli V, Leo E, Bernabei MT, Cameroni R. Protein immobilization in crosslinked alginate microparticles. J Microencap 2002; 19(1): 37-44.

Wassilak SGF, Roper MH, Murphy TV, Orenstein WA. Tetanus toxoid. In Vaccines; Plotkin SA, Mortimer EA, Ed., Saunders: Philadelphia: 4th ed., 2002: 745-781.

Esparaza I, Kissel T. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. Vaccine 1992; 10(10): 714-720.

Chang AC, Gupta RK. Stabilization of Tetanus Toxoid in Poly(DL-lactic-co-glycolic acid) Microspheres for the Controlled Release of Antigen. J Pharm Sci 1996; 85(2):129-132.

Grewal HMS, Karlsen TH, Vetvik H, Ahren C, Gjessing HK, Sommerfelt H, Haneberg B. Measurement of specific IgA in fecal Extracts and intestinal lavage fluid for monitoring of mucosal immune responses. J Immun Methods 2000; 239: 53-62.

Forrest BD. Effects of sample processing on the measurement of specific intestinal IgA immune response. Vaccine 1992; 10(11): 802-805.

Xing DKL, McLellan K, Corbel MJ, Sesardic D. Estimation of Antigenic Tetanus Toxoid Extracted from Biodegradable Microspheres. Biologicals 1996; 24: 57-65.

Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003; 250: 215-226.

Berger J, Resist M, Mayer JM, Felt O, Peppas NA, Gurny R. Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm 2004; 57: 19-34.

Liu WG, Kang DY. Chitosan and Its derivatives – a promising non viral vector for gene transfection. J Contr Rel 2002; 83:1-11.

Calvo P, Renuman-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997; 63: 125-132.

Elgersma AV, Zsom RLJ, Norde W, Lyklema J. The adsorption of bovine serum albumin on positively and negatively charged polystyrene lattices. J Colloid Int Sci 1990; 138: 145-156.

Barichello JM, Moriko M, Takayama K, Nagai T. Encapuslation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999; 25: 471-476.

Roberts GAF. Chitin Chemistry, MacMillan Press: London, 1992: 203-206.

Mi FL, Shyu SS, Wong TB, Jang SF, Lee ST, Lu KT. Chitosan polyelectrolyte complexation for the preparation of gel beads and controlled release of anti-cancer drug. II Effect of pH-dependent ionic crosslinking or interpolymer complex using tripolyphosphate or polyphosphate as reagent. J Apl Polym Sci 1999; 74:1093-1107.

Brange J, Langkjaer L. Chemical stability of insulin, 3. Influence of excipients, formulation and pH. Act Pharm Nord 1992; 4: 149-158.

Ma Z, Yeoh HH, Lim LY. Formulation pH modulates the interaction of Insulin with chitosan nanoparticles. J Pharm Sci 2002; 91(6): 1396-1404.

Downloads

Published

2007-09-20

How to Cite

1.
AHIRE V, DOSHI J, RAVETKAR S, SAWANT K. Oral delivery system for tetanus toxoid. Ars Pharm [Internet]. 2007 Sep. 20 [cited 2024 May 20];48(3):275-96. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4991

Issue

Vol. 48 No. 3 (2007)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).